Exelixis (EXEL) Stock Gains On Positive Phase 3 Data

Exelixis, Inc. (NASDAQ: EXEL) Exelixis stock is having an incredible day in the market today after the company announced positive top-line results from it’s phase 3 trial of cabozantinib. The trial compared cabozantinib to everolimus in the treatment of 658 patients who suffer from metastatic renal cell carcinoma and who have experienced disease progression following … Read more

Exelixis (EXEL) Stocks | Will Upward Momentum Continue?

While Exelixis (EXEL) has struggled over the past few years, it finally seems like the stock is starting to keep long term price gains going. While the upward momentum started in December of 2014, the stock has grown at an astonishing rate throughout the past month. So, today we’ll talk about what’s causing the movement … Read more

Biotech News 2/16/15 to 2/20/15

Oncolytics Biotech (ONCY) Shares of Oncolytics gained about 36% on 2/17/15 when it had announced that the company received FDA Orphan Drug Designation status for its pancreatic cancer drug Reolysin. Reolysin is a variant of the ReoVirus which occurs naturally in the environment. Oncolytics has engineered Reolysin to multiply at an alarming rate inside of … Read more